|

The LIFESTYLE PETS research and development team placed the company in a unique position to produce the world's first
scientifically-proven hypoallergenic cat, followed by a true
hypoallergenic dog. Our company's founder is the developer of ground
breaking veterinary molecular diagnostics technologies with a keen focus
on animal genetics.
A glycoprotein in cats (Fel d 1) and
dogs (Can d1) secreted by the sebaceous glands, are the major pet allergens.
These allergens are found in the fur, saliva, urine, mucous, salivary glands, and hair roots of
cats and dogs.
The Fel d 1 gene present in standard cats and the Can d 1 gene present
in standard dogs is responsible for the production of these proteins.

Starting with sophisticated genetic
testing technologies, the LIFESTYLE PETS team and
outside consultants
began by focusing on the particular gene that produces the glycoproteins. The process uses gene sequencing to detect rare naturally occurring genetic
divergences in our pets. LIFESTYLE PETS then targeted those divergences that could potentially
produce kittens and puppies with a natural change in the structure of the Fel d 1
and Can d 1 allergens produced by these genes.
Using sophisticated bioinformatics to
manage our breeding
programs, the result was cats and dogs with a naturally occurring divergent gene that produces a
different version of the relevant protein - and one that the human body does not
recognize as an allergen.
Beginning with our first
hypoallergenic pet, the ALLERCA GD, the company conducted controlled
trials exposing volunteers with
known feline allergies to both ALLERCA GD cats and non-GD cats. A
double-blind study conducted by world renowned UCLA allergist, Dr.
Sheldon Spector confirmed that none of the human subjects exposed to the ALLERCA GD cats reacted in
any
way. When these same volunteers were exposed to non-GD cats, the subjects demonstrated classic
symptoms of a feline allergic reaction, including watery eyes, runny
noses, hives and itchy skin.
* Patents Pending
Click HERE to
subscribe to our newsletter.
|